Drug Patents owned by Mirati Theraps
1. List of Krazati drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10689377 | MIRATI THERAPS | KRas G12C inhibitors |
May, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 12, 2027 |
Drugs and Companies using ADAGRASIB ingredient
NCE-1 date: 2026-12-12
Market Authorisation Date: 12 December, 2022
Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda approved test, who have received at least one prior system...
Dosage: TABLET;ORAL
More Information on Dosage
KRAZATI family patents
7
United States
2
Japan
2
European Union
1
Israel
1
Singapore
1
Colombia
1
Brazil
1
Ukraine
1
South Africa
1
Philippines
1
EA
1
Canada
1
Australia
1
Korea, Republic of
1
Chile
1
Taiwan, Province of China
1
China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic